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A B S T R A C T
AngII (angiotensin II) induces atherosclerosis and AAAs (abdominal aortic aneurysms) through
multiple proposed mechanisms, including chemotaxis. Therefore, we determined the effects of
whole-body deficiency of the chemokine receptor CCR2 (CC chemokine receptor 2) on these
diseases. To meet this objective, apoE (apolipoprotein E)−/− mice that were either CCR2+/+ or
CCR2−/−, were infused with either saline or AngII (1000 ng · kg−1 of body weight ·min−1) for
28 days via mini-osmotic pumps. Deficiency of CCR2 markedly attenuated both atherosclerosis
and AAAs, unrelated to systolic blood pressure or plasma cholesterol concentrations. During the
course of the present study, we also observed that AngII infusion led to large dilatations that
were restricted to the ascending aortic region of apoE−/− mice. The aortic media in most of the
dilated area was thickened. In regions of medial thickening, distinct elastin layers were discernable.
There was an expansion of the distance between elastin layers in a gradient from the intimal to
the adventitial aspect of the media. This pathology differed in a circumscribed area of the anterior
region of ascending aortas in which elastin breaks were focal and almost transmural. All regions of
the ascending aorta of AngII-infused mice had diffuse medial macrophage accumulation. Deficiency
of CCR2 greatly attenuated the AngII-induced lumen dilatation in the ascending aorta. This new
model of ascending aortic aneurysms has pathology that differs markedly from AngII-induced
atherosclerosis or AAAs, but all vascular pathologies were attenuated by CCR2 deficiency.
INTRODUCTION
Many studies have demonstrated that chronic AngII
(angiotensin II) infusion into hypercholesterolaemic mice
augments development of atherosclerosis and promotes
formation of AAAs (abdominal aortic aneurysms) [1–8].
Both vascular pathologies are characterized by macro-
phage accumulation. In AngII-induced atherosclerosis,
the macrophage accumulation is restricted to the intima,
while this cell type is initially present as a focal accumula-
tion in the media within the AAA-prone region. As AAAs
progress, abundant numbers of macrophages accumulate
in the adventitia [9]. Despite the differences in arterial
regions that accumulate macrophages in AngII-induced
atherosclerosis and AAAs, both pathologies are reduced
by deficiency in the chemokine receptor CCR2 (CC
chemokine receptor 2) on bone-marrow-derived cells [5].
The original intent of the present study was to define
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the effects of whole-body deficiency of CCR2 in the de-
velopment of AngII-induced atherosclerosis and AAAs.
During the present study, we also observed region-
specific changes localized to the ascending aortic region.
Ascending aortic dilatation is a salient feature of several
disease states including Marfan’s syndrome and related
disorders that have been associated with mutations in
fibrillin-1 [10]. Evidence for this causal role has been
provided by development of mice with manipulations
of the fibrillin-1 gene. Mice that are hypomorphic for
fibrillin-1 develop aortic dilatation associated with elastin
fragmentation and macrophage infiltration [11]. Fibrillin-
1 has also been manipulated in another mouse model
by creation of heterozygous mice expressing a mutation
generated by substitution of Cys→Gly at position
1039 (C1039G), and these mice also exhibit aortic
dilatation [12]. Although mutations in fibrillin-1 were
initially thought to exert their effects through structural
deficiencies of connective tissue, it is now known that
these variants lead to enhanced activity of TGF-β
(transforming growth factor-β) [13]. The causal role
of enhanced TGF-β signalling in the development of
ascending aortic aneurysms was demonstrated by the
ablation of the pathology by administration of a TGF-β-
neutralizing antibody [12]. Ascending aortic aneurysms
were also ablated by administration of losartan into
fibrillin-1 mutant transgenic mice. Losartan was the
first developed antagonist against AT1 (AngII type
1) receptors [14], and it has several other well-
defined effects, including influencing the production
of prostaglandins and NO and inhibiting the effects of
thromboxane A2, tachykinin and imidazoline receptors
[15]. Currently, no other AT1 receptor antagonists
prevent ascending aortic arch aneurysms in transgenic
mice expressing the C1039G fibrillin-1 mutation. Since
losartan has well defined ancillary effects, additional
studies are needed to determine whether AngII directly
promotes ascending aortic aneurysms.
Given the interest in a potential role for AngII in the
development of experimental and human ascending aortic
arch aneurysms [12,16], we focused on characteristics
and mechanisms of aneurysm formation in the ascending
aorta. This occurred in the same mice that had
the previously described vascular effects of AngII of
augmented atherosclerosis and development of AAAs.
The vascular tissue characteristics of ascending aortic
aneurysms were distinctly different from aneurysms
formed in the abdominal aorta. This included an
abundance of macrophages throughout the aortic media
of the aneurysmal regions. Since CCR2 has been invoked
as a chemoattractant mechanism of other AngII-induced
vascular pathologies [5,17,18], we examined the role of
this chemokine receptor on the development of ascending
aortic aneurysms. Moreover, we contrasted effects of
CCR2 deficiency on ascending aortic aneurysms to
atherosclerosis and AAAs.
MATERIALS AND METHODS
Animals
ApoE−/−×CCR2+/− mice (backcrossed ten times in
a C57BL/6 background) were developed in Dr
Charo’s laboratory and have been described previously
[19,20]. Male littermates with either CCR2+/+ or
CCR2−/− genotypes were derived from the breeding of
apoE−/−×CCR2+/− parental pairs. Mice were housed
under barrier conditions with food and water provided
ad libitum. All studies were performed with the approval
of the University of Kentucky Institutional Animal Care
and Use Committee.
Diet and AngII infusions
Mice used in studies were initially fed a standard
laboratory diet. To promote a hypercholesterolaemic
state, the diet was changed to one containing 0.15 %
cholesterol and 21 % (w/w) milk fat diet (TD 88137;
Harlan Teklad) 1 week prior to pump implantation
and throughout infusion. AngII (1000 ng · kg−1 of body
weight · min−1) or saline were infused subcutaneously
via Alzet mini-osmotic pumps (Model 2004; Durect) for
28 days as described previously [1].
Blood pressure measurement
Systolic blood pressure was measured in conscious mice
using a computerized tail cuff method (BP-2000; Visitech
Systems) [21]. All mice were acclimated to the system for
1 week prior to the start of the study.
Serum lipids and lipoprotein
determination
Blood was collected by cardiac puncture in anaesthetized
(ketamine/xylazine, 100/10 mg/kg of body weight,
intraperitoneally) mice and was centrifuged at 376 g
for 20 min. Serum was subsequently collected and
frozen at −80 ◦C until assayed. Serum total cholesterol
concentrations were determined using enzymatic assay
kits (cat. no. 439-17501; Wako). Lipoprotein cholesterol
distributions were evaluated in individual serum samples
(50 μl) from at least five mice in each group after
fractionation by size-exclusion chromatography on a
single Superose 6 column [22]. Fractions were collected,
and cholesterol concentrations were determined with an
enzyme-based kit.
Vascular pathology
After blood collection, saline was perfused through the
left ventricle of the heart. Aortas from the ascending
region to the bifurcation of the femoral arteries were
dissected free and fixed in formalin overnight. Following
fixation, adventitial tissue was removed, and aortas were
cut longitudinally and pinned. Photographs of aortic
intimas were acquired using a Nikon SMZ800 dissecting
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Table 1 Effects of CCR2 deficiency on apoE−/− mice infused with either saline or AngII
Values are presented as means+− S.E.M. ∗P < 0.05 and †P < 0.001 for comparisons of AngII and saline infusion within genotypes;
‡P < 0.001 for comparisons of AngII infusion between genotypes.
Infusion Genotype n Body weight (g) Serum cholesterol (mg/dl) Blood pressure (mmHg)
Saline CCR2+/+ 9 28.5+− 0.5 703+− 18 120+− 3
CCR2−/− 9 28.5+− 0.6 688+− 35 128+− 4
AngII CCR2+/+ 16 27.4+− 0.5 656+− 24 142+− 4*
CCR2−/− 19 28.1+− 0.8 820+− 20†‡ 142+− 5*
scope and Nikon digital DXM 1200 camera. The extent
of dilatation and area was quantified in aortic arches
using Image-Pro software (MediaCybernetics) [23,24].
Diameters were calculated from measurements of aortic
arch circumferences. Intimal areas were quantified from
regions of ascending arches protruding from the ventricle
to 3 mm proximal from the subclavian artery. After
histological staining, cross-sections of ascending aortas
were magnified × 400 and photographed using a Nikon
Optiphot-2 microscope and Spot camera (RT Color
Diagnostics). Medial thicknesses of ascending aortas
were measured from the inner to outer elastic laminae
(n= 3–6 mice/group). Aneurysms in abdominal aortas
were measured at the maximal width of the external
surface [25]. Detailed descriptions of measurement of
en face and aortic root atherosclerosis have been described
previously [23,24]. Briefly, atherosclerosis in the intima
surface was determined by measurements of areas covered
by grossly discernable lesions. In sections from aortic
roots, measurements were performed on Oil-Red-O-
stained serial tissue sections that are 80 μm apart that
encompassed the entire lesion (generally, nine sections
spanning 720 μm).
Histology and immunostaining were performed as
described previously [25]. The following histological
stains were used: haematoxylin and eosin for gross
morphology and Gomori trichrome for collagen and
smooth muscle cells. Macrophages were immunos-
tained using an antiserum (dilution 1:1000, cat. no.
AIAD31240; Accurate Chemical). We also attempted
to immunostain for MCP-1 (monocyte chemoattractant
protein-1) (cat. no. SC-1784 and SC-1785; Santa Cruz
Biotechnology; cat. no. AB72012.50; Abcam; cat. no.
AAM43; Serotec) and CCR2 (cat. no. 2068-1; Epitomics;
cat. no. AVARP6003; Avia; cat. no. GTX45788;
GeneTex; cat. no. sc-6227 and sc-6228, Santa Cruz
Biotechnology).
Statistics
Means and S.E.M. were calculated for each parameter.
Statistical analyses were performed using SigmaStat. In
experiments with more than one experimental group,
differences were evaluated using a two-way ANOVA,
and significant interactions analysed using a Tukey
post-hoc test for all pairwise comparisons. Data were
analysed to ensure appropriate use of parametric or
non-parametric statistics. Fisher’s exact test was used to
determine differences among groups in the incidence of
aneurysm formation. Values of P< 0.05 were considered
statistically significant.
RESULTS
Whole-body CCR2 deficiency attenuated
AngII-induced atherosclerosis and AAAs
Infusion of AngII (1000 ng · kg−1 of body weight · min−1)
into apoE−/− mice fed a saturated-fat-enriched diet had
no significant effect on body weight, serum cholesterol
concentrations or lipoprotein cholesterol distribution,
but increased systolic blood pressure (Table 1), as
described previously [7,8,21,26]. CCR2 deficiency had
no effect on AngII-induced increases in blood pressure,
while causing a small increase in serum cholesterol
concentrations (Table 1). Size-exclusion chromatography
demonstrated that the increase was due to increased
LDL (low-density lipoprotein)-cholesterol (results not
shown).
Infusion of AngII into hypercholesterolaemic mice
augmented atherosclerosis and led to development
of AAAs, as described previously [7,8]. Whole-body
deficiency of CCR2 reduced the size of atherosclerotic
lesions in both the en face measurement of aortic intima
(Figure 1A) and in tissue sections from the aortic
sinus (Figure 1B), and attenuated development of AAAs
(Figure 1C). The extent of these changes were similar
to that described previously in irradiated apoE−/− mice
that were repopulated with bone-marrow-derived cells
harvested from CCR2−/− mice [5].
AngII infusion promoted ascending aortic
aneurysms
Compared with saline-infused apoE−/− mice, infusion
of AngII led to gross changes that were present from
the ascending aorta to just proximal of the subclavian
artery (Figure 2). These changes included dilatation of
the ascending aorta and thinning of the anterior aspect
of this region.
The composition of aortic tissues was defined on tissue
sections of ascending aorta as shown in Figure 3. Medial
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Figure 1 Deletion of CCR2 attenuates the development of
AngII-induced atherosclerosis and AAAs
Each symbol represents individual animals, diamonds represent means, and bars
are S.E.M. (A) Area of aortic intima covered with atherosclerotic lesions as
measured by en face analysis. *P < 0.001 and #P < 0.005 for comparisons of
saline and AngII infusions within genotypes; †P < 0.001 for comparisons
of CCR2+/+ and CCR2−/− within AngII-infused groups. (B) Mean lesion area
per section in the aortic root. *P = 0.003 for comparison of saline and AngII
infusion within CCR2+/+ groups; †P < 0.001 for comparisons of CCR2+/+ and
CCR2−/− within AngII-infused groups. P < 0.005 for comparisons of saline
and AngII infusions within genotypes. (C) Aneurysm size was measured as width
of abdominal aorta. *P < 0.001 for comparisons of saline and AngII infusions;
#P < 0.001 for comparisons of CCR2+/+ and CCR2−/− within AngII-infused
groups.
hypertrophy, collagen deposition and macrophage
accumulation were not seen in ascending aortic tissue
sections from saline-infused mice (Figures 3A, 3D
and 3G respectively). Tissue sections from ascending
aortas of AngII-infused mice exhibited hypertrophy
of the intra-lamellar spaces. The intra-lamellar spaces
on the adventitial aspect of vessels exhibited the
most extensive hypertrophy, collagen deposition and
macrophage accumulation (Figures 3B, 3C, 3E, 3F, 3H
and 3I). Areas with medial changes were not associated
with the presence of atherosclerosis in adjacent intima.
Macrophage accumulation was predominantly in areas
that had pronounced hypertrophy and extracellular
matrix disruption. Unlike the effects we observed
previously during AngII infusion in osteopetrotic mice
[27], we did not observe the presence of erythrocytes
between elastin layers with ascending aortic pathology.
At the anterior aspect of aortic arches, there was frequent
destruction of elastin fibres, and the integrity of the artery
was largely maintained by collagen fibres in the adventitia
(Figures 3C, 3F and 3I). Unlike AAAs [9], we did not
detect the presence of T-lymphocytes in ascending aortic
aneurysms (results not shown). We were also unable to
detect immunostaining on sections of ascending aortic
aneurysms that was specific for either CCR2 or MCP-1
using multiple antibodies.
Whole-body CCR2 deficiency attenuated
AngII-induced pathological changes in the
ascending aorta
With the exception of the anterior region of ascending
aortas, AngII infusion increased aortic wall thickness,
which presumably accounted for the increased vessel
opacity. Aortic wall thickness was measured from the
inner to outer elastic lamina. AngII infusion increased
aortic wall thickness (Figure 4) that was ablated in
CCR2-deficient mice (P= 0.007 when compared with
AngII-infused CCR2+/+ mice). Increased vessel opacity
did not result from augmented atherosclerosis, since
atherosclerosis was not uniformly distributed throughout
the ascending aorta. There was minimal change in the
aortic width in the descending aortic region of AngII-
infused mice beyond the branch of the subclavian
artery.
The severity of dilatation in the ascending aorta
was determined by measuring luminal diameters
and intimal areas. Saline-infused apoE−/− mice had
ascending aortic diameters of 0.81 +− 0.03 mm, while
AngII infusion increased diameters to 1.22 +− 0.07 mm
(Figure 5A; P< 0.05). CCR2 deficiency decreased
luminal diameters of ascending aortas during AngII
infusion to 0.9 +− 0.02 mm (P< 0.05). The en face
intimal areas of aortic arches were measured from
the ascending aorta to 3 mm proximal from the left
subclavian branch. Ascending aortic areas of saline-
infused genotypes were between 14 and 15 mm2, while
AngII infusion in CCR2+/+ mice increased the area to
24.6 +− 0.8 mm2 (Figure 5B; P< 0.001). CCR2 deficiency
reduced ascending aortic intima areas to 18.5 +− 0.5 mm2
(P< 0.001).
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Figure 2 AngII infusion induces ascending aortic aneurysms
Examples of aortic arches from apoE−/− mice infused with either saline (A) or AngII (B). The blue lines designated as 1 and 2 represent the areas sectioned and
represented in Figure 3.
Figure 3 Histological and cellular characteristics of AngII-induced ascending aortic aneurysms
(A), (D) and (G) are harvested from a saline-infused CCR2+/+ mouse. Sections derived from the area defined by line 1 in Figure 2 are shown in (B), (E) and (H),
and the anterior portion of the region in line 2 is represented in (C), (F) and (I). Sections were stained with haematoxylin and eosin (A–C), Gomori trichrome
(D–F) and immunostained for macrophages (positive cells are red; G–I). The orientation of aortas is described in (A), (B) and (C) by L, lumen; M, media; A, adventitia.
Magnification, × 400.
DISCUSSION
CCR2 is the only known functional receptor for
MCP-1 in macrophage migration [18,28]. Deficiency
of this receptor on bone-marrow-derived cells re-
duces atherosclerosis in hypercholesterolaemic mice
[19,29,30]. One study has also demonstrated that
CCR2 deficiency in chimaeric mice developed by
bone marrow transplantation attenuated AngII-induced
atherosclerosis and AAAs [5]. However, bone marrow
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Figure 4 Deletion of CCR2 attenuates AngII-induced as-
cending aorta medial expansion
Ascending aortic thickness was measured from images (n = 3–6 mice/group)
using image analysis software. Histobars represent groups, and error bars
represent S.E.M.. *P = 0.002 for comparison of saline and AngII. #P = 0.007
for comparison of CCR2+/+ and CCR2−/− within AngII infusion.
Figure 5 Deletion of CCR2 attenuates AngII-induced as-
cending aortic aneurysms
Ascending aortic diameters (A) and intimal areas (B) of arch regions were
measured from images of pinned aortas using image analysis software.
Circles and triangles represent individual mice, diamonds are means and bars
represent S.E.M. (A) *P < 0.001 for comparison of AngII and saline infusion
in both genotypes. #P < 0.001 for comparison of genotype within AngII
infusion groups. (B) *P < 0.001 for comparison of AngII and saline infu-
sion in CCR2+/+ mice. #P < 0.001 for comparison of CCR2+/+ and CCR2−/−
mice infused with AngII. †P < 0.001 for comparison of saline and AngII infusion
in CCR2−/− mice.
transplantation can lead to differences in the development
of atherosclerosis and AAAs [25,31]. No previous
studies have demonstrated the effects of whole body
CCR2 deficiency on the development of AngII-
induced vascular diseases. In the present study, it
was demonstrated that whole-body CCR2 deficiency
attenuated both AngII-induced atherosclerosis and
AAAs.
Ascending aortic dilatation, with subsequent rupture,
is the most life-threatening manifestation of Marfan’s
disease [32]. Previous studies in mice expressing a
fibrillin-1 mutant have demonstrated a similar pathology
to that generated during AngII infusion in the present
study [12]. These similarities include dilatation that is
localized to the ascending aorta, medial thickening and
elastin fragmentation. Thus, the results of the present
study are complementary to the previously described
effect of losartan in fibrillin-1 mutant mice being due
to antagonism of the effects of AngII.
Many publications have demonstrated that AngII
infusion leads to aneurysmal formation in the abdominal
aorta [1,4,33–36]. In the present study, we demonstrated
that AngII infusions led to large lumen dilatations of the
ascending aorta, as has been described previously for the
abdominal aorta [37]. However, there are marked differ-
ences in the pathological characteristics of aneurysmal
formation in these two regions. AAAs form rapidly as
a consequence of a highly localized transmural elastin
disruption that colocalizes with focal medial macrophage
accumulation [9]. Adventitial thrombi form adjacent to
medial ruptures that promote an intense inflammatory
response with the recruitment of macrophages. During
subsequent remodelling, aneurysmal tissue contains
abundant macrophages, with the accumulation of both
T- and B-lymphocytes [9]. In contrast, ascending aortas
exhibit extensive elastin fragmentation following infusion
of AngII, but not transmural as seen in AAAs. In addition,
the distance between the elastin layers progressively
increases towards the adventitial side of ascending
aortas. Regions of greatest elastin disruption and intra-
laminar expansion were associated with macrophage
accumulation. Furthermore, unlike AAAs in which
macrophages have been detected at focal sites in the aortic
media at an early phase of the disease, AngII promoted
macrophage accumulation throughout the medial layers
of ascending aortas. At the anterior aspect of ascending
aortas, a different pathology was observed in which there
was a focal thinning compared with the surrounding
hypertrophic areas. Furthermore, we did not detect
thrombotic material at this anterior region. Thus, the
highly contrasting pathologies between the aneurysms
in abdominal aortas compared with ascending aortas
are indicative of different mechanisms by which AngII
generates these diseases.
AngII-induced pathology in ascending aortas extended
proximal to the subclavian artery, while the descending
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portion of the thoracic aorta was spared. This localization
strongly resembles the distribution of dilatation observed
in mice expressing a mutation of fibrillin-1 [12]. The
basis for specificity of the dilatation is presumably due
to regional differences that exist throughout the aorta.
The aorta has considerable functional diversity of smooth
muscle cells that may be based on developmental origin
[31]. Using mice expressing Cre under the control of
Wnt1 in combination with a floxed Rosa26 reporter, it
has been demonstrated that the region from the ascending
aorta to just distal of the subclavian artery are populated
by smooth muscle cells of neural crest origin [38]. This
distribution is strikingly similar to the region of ascending
aortic aneurysms promoted by AngII that are shown in
Figure 2. It remains to be determined what property
of these cells enable AngII to promote this localized
pathology.
Previous studies using fibrillin-1 mutant transgenic
mice demonstrated that while losartan and propranolol
administration resulted in comparable haemodynamic
effects, only losartan administration reduced ascending
aortic aneurysms [12.] Thus, blood pressure did not
appear to contribute to aortic aneurysms in this mouse
model of Marfan’s syndrome. In the present study,
the infusion of 1000 ng · kg−1 of body weight · min−1
of AngII was associated with an increase in systolic
blood pressure. However, the AngII-induced increases
in systolic blood pressure were not influenced by whole-
body CCR2 deficiency, despite the attenuated size of the
ascending aortic aneurysms. Thus, in a similar manner to
previously described for AngII-induced atherosclerosis
[2] and AAAs [39], the increase in blood pressure from
AngII infusion is not responsible for the development of
ascending aortic aneurysms.
Ascending aortas from AngII-infused mice had
considerable accumulation of macrophages throughout
the media that have a preponderance on the adventitial
side of the vessel. Infusion of AngII into C57BL/6
mice has previously been shown to promote macrophage
accumulation predominantly in the adventitia [17].
However, that study was performed in the descending
thoracic aorta, which did not exhibit dilatation. Thus,
CCR2 may be the major stimulus for the recruitment
of macrophages to the aortic adventitia. Therefore, the
combined results of Bush et al. [17] and the present
study demonstrate that another mediator contributes to
migration of macrophages from the adventitia into the
media. The identification of this putative mediator is
unknown.
It is of interest that AngII infusion generates three
distinct vascular pathologies within the aorta that have
specific locations and pathological characteristics. A
unified finding in the AngII-induced vascular diseases
was macrophage accumulation. However, even within
this unified finding, there are many interesting differ-
ences. For AngII-induced atherosclerosis, macrophages
are only recruited to the intima and are rarely present
in the media. In AngII-induced AAAs, there are initial
small focal regions of macrophage accumulation in the
media. In contrast, we describe macrophage accumulation
in AngII-induced ascending aortic aneurysms occurring
throughout the circumference of the artery and
predominantly on the adventitial side of the aorta. It
will be a fascinating challenge to determine why CCR2
deficiency attenuates macrophage accumulation in these
aortic regions.
In summary, the present study is the first description of
AngII infusion leading to a highly localized pathology
of dilatation and medial remodelling and destruction that
is localized to the ascending aortic region. A role of
AngII in ascending aortic aneurysms of Marfan’s patients
is consistent with the benefits of ACE (angiotensin-
converting enzyme) inhibition on aortic dilatation in
these patients [40,41]. Further evidence will be derived
from a currently ongoing clinical trial that is assessing
the effects of losartan in Marfan’s patients [42]. The
pathology of AngII-induced ascending aortic aneurysms
is distinct from that described previously for AAAs and
will require further study to fully elucidate the basis for
the disparate pathological characteristics of aneurysms
that are localized to ascending compared with abdominal
aortic regions.
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